Asarina Pharma AB (publ) (APS.F)

0.0632 +0.0006 (+0.96%) As of 09:15AM CEST. Market open.

Asarina Pharma AB (publ)

Karolinska Institutet Science Park
Fogdevreten 2
Solna 171 65
Sweden
46 8 52 48 44 82
https://www.asarinapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 0

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Peter Nordkild M.D.	CEO & Chief Medical Officer	1.82M	N/A	1955
Mr. Jakob Dynnes Hansen M.Sc., MBA	Chief Financial Officer	N/A	N/A	1955
Mr. Torbjörn Bäckström M.D., Ph.D.	Chief Science Officer & Chairman of Scientific Advisory Board	N/A	N/A	1948
Mark DuBois	Communications Manager	N/A	N/A	N/A
Mr. Otto Skolling M.Sc	Chief Business Officer	N/A	N/A	1961

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its flagship product is Sepranolone, which is used for the treatment of menstrual migraine and Tourette syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. The company was incorporated in 2005 and is based in Solna, Sweden.

Corporate Governance

Asarina Pharma AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.